1. Scrip
  2. >>New Products

Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches

 
• By Jessica Merrill

US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.

apples alike
Teva remains enthusiastic about biosimilars. • Source: Shutterstock

Teva Pharmaceutical Industries Ltd. is optimistic about two big upcoming biosimilar launches in the US in the immunology space despite market dynamics that have prevented substantial biosimilar uptake. The company is preparing to launch Simlandi (adalimumab-ryvk), a biosimilar version of AbbVie Inc.’s Humira (adalimumab), within weeks and Selarsdi (ustekinumab-aekn), a biosimilar version of Johnson & Johnson’s Stelara (ustekinumab), next year.

Teva’s partner, Alvotech , developed the biosimilars, with Simlandi receiving US Food and Drug Administration approval in February for all of Humira’s indications, including rheumatoid arthritis, plaque psoriasis and ulcerative colitis. (Also see "Alvotech FDA Approval Clears Path To Challenge Humira" - Generics Bulletin, 26 February, 2024.) The FDA approved Selarsdi for Stelara’s dermatology indications, plaque psoriasis and psoriatic arthritis, on 16 April

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

Pipeline Watch: Five Approvals And One Phase III Readout

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Merck KGaA Seals SpringWorks Buy

 
• By Kevin Grogan

The German group is paying $3.9bn to get hold of the US firm and its two approved products.

More from Scrip

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.